Psyence Biomedical Ltd. Warrant
PBMWW
About: Psyence Biomedical Ltd is a life science biotechnology company pioneering the use of natural psychedelics in mental health and wellbeing. It develops natural psilocybin products for the healing of psychological trauma and its mental health consequences in the context of palliative care. The company has commenced the clinical trial process to evaluate the safety and efficacy of its product candidates. It cultivates natural psilocybin mushrooms at its federally licensed facility in Southern Africa. This product is produced for export to its partners across the world to be processed into a standardized encapsulated product.
Employees: 12
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
34.26% more ownership
Funds ownership: 12.57% [Q1] → 46.83% (+34.26%) [Q2]
28% more capital invested
Capital invested by funds: $96.4K [Q1] → $124K (+$27.3K) [Q2]
0% more funds holding
Funds holding: 23 [Q1] → 23 (+0) [Q2]
0% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 3
Financial journalist opinion
We haven’t received any recent news articles for PBMWW